目的：研究β-受体阻滞剂治疗老年慢性心力衰竭患者的疗效。方法选取90例老年慢性充血性心力衰竭患者（年龄＞65岁），其中48例常规抗心力衰竭治疗作为对照组，治疗组42例在常规治疗基础上给予口服酒石酸美托洛尔（倍他洛克）6．25 mg／次，2次／d，逐渐加量，2周剂量加倍1次，观察疗效。结果治疗组临床症状改善总有效率为92．9％，明显高于对照组（75．0％）；另外，与对照组相比，治疗组患者服用倍他洛克后，静息心率明显降低，地高辛和胺碘酮的使用率减少，差异均有统计学意义（P＜0．05）。结论长期规范应用β-受体阻滞剂能显著改善老年慢性心力衰竭患者的临床症状，更易达到靶目标心率，降低了病死率和合并症的发生。%Objective To study the efficacy of β-blocker in the treatment of senile patients with chronic heart failure. Methods Ninety senile patients with chronic congestive heart failure ( age>65 years) were selected for the study.Of all the cases, 48 were given routine anti-heart failure therapy and were set as the control group, while another 42 cases were set as the treatment group, that was given oral Betaloc at a dosage of 6.25 mg/once, twice a day, with an increased dosage of twice as much as the original dosage within 2 weeks.Then, close observation was made on the therapeutic efficacy.Results Total effective rate for the improvement of clinical symptoms in the treatment group was 92.9%, which was significantly higher than that of the control group (75%).In addi-tion, as compared with the patients in the control group, the heart rate of the patients at rest in the treatment group following medication of Betaloc was significantly decreased, and the consumption of digoxin and amiodarone was decreased also.Statistical significance could be seen when comparisons were made between the 2 groups (P<0.05).Conclusion Prolonged and standardized application ofβ-bloc-ker could significantly improve the clinical symptoms of senile patients with chronic heart failure, thus facilitating to reach the desired target heart rate, decreasing mortality and the incidence of complications.
展开▼
